Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Diabetic Wound Healing and Activation of Nrf2 by Herbal Medicine.

Senger DR, Cao S.

J Nat Sci. 2016;2(11). pii: e247.

3.

Activation of the Nrf2 Cell Defense Pathway by Ancient Foods: Disease Prevention by Important Molecules and Microbes Lost from the Modern Western Diet.

Senger DR, Li D, Jaminet SC, Cao S.

PLoS One. 2016 Feb 17;11(2):e0148042. doi: 10.1371/journal.pone.0148042. eCollection 2016.

4.

Calpain inhibition improves collateral-dependent perfusion in a hypercholesterolemic swine model of chronic myocardial ischemia.

Sabe AA, Potz BA, Elmadhun NY, Liu Y, Feng J, Abid MR, Abbott JD, Senger DR, Sellke FW.

J Thorac Cardiovasc Surg. 2016 Jan;151(1):245-52. doi: 10.1016/j.jtcvs.2015.08.101. Epub 2015 Sep 3.

5.

Angiogenesis.

Senger DR, Davis GE.

Cold Spring Harb Perspect Biol. 2011 Aug 1;3(8):a005090. doi: 10.1101/cshperspect.a005090. Review.

6.

Moderation of calpain activity promotes neovascular integration and lumen formation during VEGF-induced pathological angiogenesis.

Hoang MV, Nagy JA, Fox JE, Senger DR.

PLoS One. 2010 Oct 25;5(10):e13612. doi: 10.1371/journal.pone.0013612.

7.

Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1.

Hoang MV, Nagy JA, Senger DR.

Blood. 2011 Feb 3;117(5):1751-60. doi: 10.1182/blood-2010-05-286831. Epub 2010 Oct 28.

8.

Cdc42-mediated inhibition of GSK-3β improves angio-architecture and lumen formation during VEGF-driven pathological angiogenesis.

Hoang MV, Nagy JA, Senger DR.

Microvasc Res. 2011 Jan;81(1):34-43. doi: 10.1016/j.mvr.2010.09.001. Epub 2010 Sep 16.

9.

Moderate GSK-3β inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy.

Hoang MV, Smith LE, Senger DR.

Angiogenesis. 2010 Sep;13(3):269-77. doi: 10.1007/s10456-010-9184-y. Epub 2010 Sep 1.

10.

Calpain inhibitors reduce retinal hypoxia in ischemic retinopathy by improving neovascular architecture and functional perfusion.

Hoang MV, Smith LE, Senger DR.

Biochim Biophys Acta. 2011 Apr;1812(4):549-57. doi: 10.1016/j.bbadis.2010.08.008. Epub 2010 Sep 8.

11.

Vascular endothelial growth factor: much more than an angiogenesis factor.

Senger DR.

Mol Biol Cell. 2010 Feb 1;21(3):377-9. doi: 10.1091/mbc.E09-07-0591.

12.

Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression.

Davis GE, Senger DR.

Curr Opin Hematol. 2008 May;15(3):197-203. doi: 10.1097/MOH.0b013e3282fcc321. Review.

PMID:
18391785
13.

Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity.

Zeng H, Qin L, Zhao D, Tan X, Manseau EJ, Van Hoang M, Senger DR, Brown LF, Nagy JA, Dvorak HF.

J Exp Med. 2006 Mar 20;203(3):719-29. Epub 2006 Mar 6.

14.

VEGF-A, cytoskeletal dynamics, and the pathological vascular phenotype.

Nagy JA, Senger DR.

Exp Cell Res. 2006 Mar 10;312(5):538-48. Epub 2005 Nov 28. Review.

PMID:
16310771
15.
16.

In vivo and in vitro models of Mammalian angiogenesis.

Hoang MV, Senger DR.

Methods Mol Biol. 2005;294:269-85.

PMID:
15576918
17.

VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins.

Hong YK, Lange-Asschenfeldt B, Velasco P, Hirakawa S, Kunstfeld R, Brown LF, Bohlen P, Senger DR, Detmar M.

FASEB J. 2004 Jul;18(10):1111-3. Epub 2004 May 7.

PMID:
15132990
18.
19.

Rho activity critically and selectively regulates endothelial cell organization during angiogenesis.

Hoang MV, Whelan MC, Senger DR.

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1874-9. Epub 2004 Feb 9.

20.

Functional overlap and cooperativity among alphav and beta1 integrin subfamilies during skin angiogenesis.

Perruzzi CA, de Fougerolles AR, Koteliansky VE, Whelan MC, Westlin WF, Senger DR.

J Invest Dermatol. 2003 Jun;120(6):1100-9.

21.
22.

Molecular profiling of angiogenesis markers.

Shih SC, Robinson GS, Perruzzi CA, Calvo A, Desai K, Green JE, Ali IU, Smith LE, Senger DR.

Am J Pathol. 2002 Jul;161(1):35-41.

23.
24.

Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity.

Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith LE.

Proc Natl Acad Sci U S A. 2001 May 8;98(10):5804-8. Epub 2001 May 1.

25.

Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials.

Ali IU, Senger DR, Smith LE.

Urology. 2001 Apr;57(4 Suppl 1):143-7. Review.

PMID:
11295614
26.

VEGF expression by epithelial and stromal cell compartments: resolving a controversy.

Senger DR, Van De Water L.

Am J Pathol. 2000 Jul;157(1):1-3. No abstract available.

27.

Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.

Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR.

Nat Med. 1999 Dec;5(12):1390-5.

PMID:
10581081
28.

Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins.

Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M.

Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13612-7.

29.

Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin.

Senger DR, Perruzzi CA.

Biochim Biophys Acta. 1996 Nov 8;1314(1-2):13-24.

30.
32.

Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation.

Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR.

Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5. Review.

PMID:
7542074
33.

Osteopontin at the tumor/host interface. Functional regulation by thrombin-cleavage and consequences for cell adhesion.

Senger DR, Brown LF, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L.

Ann N Y Acad Sci. 1995 Apr 21;760:83-100. No abstract available.

PMID:
7540380
35.

Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF.

Claffey KP, Senger DR, Spiegelman BM.

Biochim Biophys Acta. 1995 Jan 5;1246(1):1-9.

PMID:
7811723
36.

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.

Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ.

Hum Pathol. 1995 Jan;26(1):86-91.

PMID:
7821921
37.
38.

Osteopontin expression and distribution in human carcinomas.

Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR.

Am J Pathol. 1994 Sep;145(3):610-23.

39.
40.

Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.

Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF.

J Exp Med. 1994 Jul 1;180(1):341-6.

41.
42.

Osteopontin: its transglutaminase-catalyzed posttranslational modifications and cross-linking to fibronectin.

Beninati S, Senger DR, Cordella-Miele E, Mukherjee AB, Chackalaparampil I, Shanmugam V, Singh K, Mukherjee BB.

J Biochem. 1994 Apr;115(4):675-82.

43.

Ultrastructural immunogold localization of osteopontin in human gallbladder epithelial cells.

Qu-Hong, Brown LF, Senger DR, Geng LL, Dvorak HF, Dvorak AM.

J Histochem Cytochem. 1994 Mar;42(3):351-61.

PMID:
8308252
44.

Vascular permeability factor, tumor angiogenesis and stroma generation.

Senger DR, Brown LF, Claffey KP, Dvorak HF.

Invasion Metastasis. 1994-1995;14(1-6):385-94. Review.

PMID:
7544775
45.

Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.

Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR.

Am J Pathol. 1993 Nov;143(5):1255-62.

46.

Calcium-binding properties of osteopontin derived from non-osteogenic sources.

Singh K, Deonarine D, Shanmugam V, Senger DR, Mukherjee AB, Chang PL, Prince CW, Mukherjee BB.

J Biochem. 1993 Nov;114(5):702-7.

47.

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.

Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF.

Cancer Res. 1993 Oct 1;53(19):4727-35.

PMID:
8402650
48.

Vascular permeability factor (VPF, VEGF) in tumor biology.

Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF.

Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24. Review.

PMID:
8281615
49.

Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.

Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF, et al.

Cancer Res. 1993 Jun 15;53(12):2912-8.

50.

Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies.

Sioussat TM, Dvorak HF, Brock TA, Senger DR.

Arch Biochem Biophys. 1993 Feb 15;301(1):15-20.

PMID:
8442657

Supplemental Content

Loading ...
Support Center